What is the yield of EBUS-TBNA for re-evaluation of previously treated non-small-cell lung cancer?
Turkish Journal of Medical Sciences · 01.01.2023 · 53 (2) · 586-593
DOI: 10.55730/1300-0144.5619 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 01.01.2023. Verfasst von Ayperi Öztürk und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Pulmonology, Atatürk Sanatoryum Training and Research Hospital, Health Science University, Ankara, Turkey. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Anthracosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background/aAim: Locoregional recurrence in lung cancer still remains an important problem. We aimed to indicate the effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for reevaluation in previously treated nonsmall cell lung cancer (NSCLC). Materials and methods: NSCLC patients who underwent EBUS for rebiopsy of suspicious recurrent or progressive lesions between January 2010 and June 2017 were reviewed. Patients were categorized into two groups based on the previous treatment modalities: Group 1 (G1) consisted of patients who had been treated with chemoradiotherapy, and Group 2 (G2) consisted of patients who had undergone radical surgery.
Results
Of 115 patients, 100 patients enrolled in the study. Of 26 patients with 35 lymph nodes in G1, malignant cells were identified in thirteen patients (50%). Anthracosis was detected in the remaining. Malignancy was detected in 28 patients (37.8%) in G2. Thirty-three patients were diagnosed as benign (24 anthracosis; 8 lymphocytes, and 1 granulomatous); 8 were not sampled, and inadequate material was obtained in five. The sensitivity, specificity, negative and positive predictive value, and overall diagnostic accuracy of EBUS-TBNA for rebiopsy in G1 were 84.8%, 100%, 89.1%, 100%, and 93.2%, respectively. These values were all perfect in G2.
Conclusion
EBUS-TBNA could be preferred as a feasible and efficient procedure for rebiopsy in previously treated NSCLC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Interventional Pulmonology, Atatürk Sanatoryum Training and Research Hospital, Health Science University, Ankara, Turkey.
- Department of Chest Diseases, Konya Numune Hospital, Konya, Turkey.
Zitieren
APA
Öztürk, A., Çiçek, T., & Yılmaz, A. (2023). What is the yield of EBUS-TBNA for re-evaluation of previously treated non-small-cell lung cancer?. Turkish Journal of Medical Sciences, 53(2), 586-593. https://doi.org/10.55730/1300-0144.5619
Vancouver
Öztürk A, Çiçek T, Yılmaz A. What is the yield of EBUS-TBNA for re-evaluation of previously treated non-small-cell lung cancer?. Turkish Journal of Medical Sciences. 2023;53(2):586-593. doi:10.55730/1300-0144.5619
BibTeX
@article{ztrk2023,
author = {Öztürk, Ayperi and Çiçek, Tuğba and Yılmaz, Aydın},
title = {What is the yield of EBUS-TBNA for re-evaluation of previously treated non-small-cell lung cancer?},
journal = {Turkish Journal of Medical Sciences},
year = {2023},
volume = {53},
number = {2},
pages = {586--593},
doi = {10.55730/1300-0144.5619}
}
EUVIMED